September 2026 quarter: revenue up 85 percent, profit after tax up 97 percent
FREDUN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations was Rs 26,585.37 lakh, up 85.2% from Rs 14,358.53 lakh in the year-ago quarter; profit after tax was Rs 1,857.42 lakh, up 96.9% from Rs 943.17 lakh. Exceptional items were nil. The statutory auditor gave an unmodified limited review. The Board also approved applying to the NSE for equity listing.
Strong sales and profit growth supports sentiment. A possible NSE listing may improve trading access and liquidity, subject to approvals.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.